Neuronetics, Inc.
NASDAQ: STIM
Company Presentation
July 2020
Disclaimers
This presentation contains estimates and other statistical data prepared by independent parties and by Neuronetics, Inc. (the "Company") relating to market size and growth and other data about the industry in which the Company operates. These estimates and data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates and data.
Certain statements in this presentation and the accompanying oral commentary are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, including statements relating to the Company's business strategy and financial metrics as well as revenue, operating expense and earnings guidance and projections for future periods, relate to future events or the future financial performance of the Company and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology, as well as the negative of such statements. All statements other than statements of historical fact may be deemed to be forward-looking statements, including those concerning any expectations regarding investment returns; any projections of financial information; any statements about historical results that may suggest trends for our business; any statements of the plans, strategies, and objectives of management for future operations; any statements of expectation or belief regarding future events, potential markets or market size, additional indications or technology developments; developments in clinical trials or regulatory review of NeuroStar Advanced Therapy System for additional indications; and any statements of assumptions underlying any of the items mentioned. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors may cause actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. The forward-looking statements in this presentation are made only as of the date hereof. Except as required by law, the Company assumes no obligation and does not intend to update these forward-looking statements or to conform these statements to actual results or to changes in the Company's expectations, assumptions, estimates and projections.
2
Presenters
3
Neuronetics Snapshot
- NeuroStar Advanced Therapy - Transcranial Magnetic Stimulation (TMS)
- Focused on psychiatric indications
-
Current Indication:
Major Depressive Disorder (MDD) in adults failed to receive satisfactory improvement from prior antidepressant medication in the - current episode
- Safe, effective and non-invasiveoffice-based treatment
- FDA cleared 2008
- CE mark (2012) and approved in Japan in September 2017. Reimbursement in Japan acquired in June 2019
4
Investment Highlights
Clinically Relevant and Differentiated Outcomes for Patients with MDD Category Leading Clinical Study Compendium
Large Direct Sales and Customer Support Team - Difficult to Replicate
Broad US Reimbursement
Favorable Psychiatrist Economics
$6.0B Targeted Annual TAM Among Psychiatrist Practices
Geographic and Potential New Indication Opportunities for Growth
Financial Profile: FY 2019 Revenue $62.7M 2019 YoY growth of 19% versus 2018. Q1 2020 Rev $11.5M versus $12.7M in 2019. Q1 2020 Ending Cash Balance, $63.6M.
5
Major Depressive Disorder
Disease Overview
- Characterized by depressed mood or loss of interest in pleasure for at least two weeks
- Periods of remission and relapse over a lifetime
- 300 million people worldwide living with depression
•
•
13 million adults with MDD in the US
3.0% incidence rate
Disease Burden
- Economic burden in US of $210 billion annually
Medical Management
- First line treatment is antidepressants with or without psychotherapy
- Care by PCP, followed by referral to psychiatrist after failed treatment attempt
MDD is a leading cause of disability and a major contributor to suicide worldwide *
*Source: https://www.who.int/news-room/fact-sheets/detail/depression
6
Transcranial Magnetic Stimulation
- TMS uses pulsed, MRI-strength magnetic field
- Induces electrical currents to stimulate specific areas of brain associated with mood
- Stimulation triggers a cascading electro-chemical effect
- Changes connections in brain structures to improve neuronal circuit activity and mood
Stimulates neurons in prefrontal cortex region of brain
Stimulated neurons release neurotransmitters
Effectiveness of TMS therapy depends on precise and targeted stimulation that is consistent and repeatable over treatment sessions
7
Limitations of Antidepressant Medications
Limited Effectiveness | ||||||
STAR*D Study1 | ||||||
Achieving Remission (HAMD 17) | ||||||
30% | 27.5% | |||||
Patients | 25% | 21.2% | ||||
20% | 17.1% | |||||
15% | ||||||
10% | 6.9% | |||||
5% | ||||||
0% | ||||||
First-Line | One-Prior | Two-Prior | Three-Prior | |||
Treatment | Treatment | Treatment | Treatment | |||
Effect | Failure | Failures | Failures | |||
(N=2,876) | (N=727) | (N=221) | (N=58) |
- Approximately 28% and 21% of patients achieved remission in their first and second medication attempts, respectively
- Likelihood of remission was limited and
declined with each new medication attempt
Treatment-Emergent Side Effects
STAR*D Study1 | ||||||
Discontinuation Due to Side Effects | ||||||
50% | ||||||
Patients | 41.4% | |||||
40% | 36.2% | |||||
30% | 23.1% | |||||
20% | 8.6% | |||||
10% | ||||||
0% | ||||||
First-Line | One-Prior | Two-Prior | Three-Prior | |||
Treatment | Treatment | Treatment | Treatment | |||
Effect | Failure | Failures | Failures | |||
(N=2,876) | (N=727) | (N=221) | (N=58) |
- Likelihood of discontinuing treatment increased with each new medication attempt
- In the fourth treatment attempt, likelihood of dropping out of treatment had more than quadrupled
- Adverse events discontinuation rate in
monotherapy 9% to 41%
8 | 1. Trivedi MH, et al. (2006). Evaluation of Outcomes with Citalopram for Depression Using Measurement-Based Care in Sequenced | ||
Treatment Alternatives to Relative Depression ("STAR*D") Implications for Clinical Practice. Am J Psychiatry, 163(1):28-40. | |||
Clinically Proven Solution
Acute Phase in Real-World Clinical Settings Study1 | Long-term Durability in Real-World Clinical Settings Study2 | |
CGI-S Outcomes | |||
70% | 58.0% | 59.4% | |
60% | |||
Patients | 50% | 37.1% | 39.9% |
40% | |||
30% | |||
20% | |||
10% | |||
0% | Overall | Low | |
(N=307) | Treatment | ||
Resistance | |||
(N=140) |
Response | Remission | |
- 1 in 2 patients respond
- 1 in 3 patients achieve remission
56.8%
34.9%
High
Treatment
Resistance
(N=167)
CGI-S Outcomes
70% | 66.1% | 68.1% | 67.7% | ||||||||
62.3% | 62.3% | ||||||||||
60% | 47.5% | ||||||||||
Patients | 50% | 41.2% | 43.2% | 44.4% | 45.1% | ||||||
40% | |||||||||||
30% | |||||||||||
20% | |||||||||||
10% | |||||||||||
0% | |||||||||||
End of | 3 Months | 6 Months 9 Months | 12 Months | ||||||||
Acute | |||||||||||
(N=257) | |||||||||||
Response | Remission | ||||||||||
- Long-termdurability has been demonstrated with
response and remission rates among users
Outcomes Registry
- World's largest registry of treatment resistant depression with over 8,900 enrolled patients, of those >5,200 evaluable patients, across >100 treatment facilities
- Remission rate of 33.2% and response rate of 62.5% for over 5,200 self-evaluating patients
- Remission rate of 52.0% and response rate of 73.2% for 1,700+ patients evaluated by clinician rating scale
9 | 1. | Carpenter L.L, et al. (2012) Depression and Anxiety, 29(7):587-596 |
2. | Dunner, D.L., et al. (2014) The Journal of Clinical Psychiatry, 75(12):1394-1401 | |
Clinically Proven Solution
Two Randomized Controlled Trials
- Sponsored largest RCT, sham-controlled TMS trial ever conducted
- Enrolled 325 adult patients with treatment resistant MDD
- Primary Efficacy Endpoint: MADRS at 4 weeks (P=0.057); not achieved but clinically meaningful improvement demonstrated
- Secondary Efficacy Endpoints Included: HAMD 17 at 4 and 6 weeks (P=0.006 and P=0.005, respectively); HAMD 24 at 4 and 6 weeks (P=0.012 and P=0.015, respectively)
- Basis of initial 510(k) clearance in 2008 - failed oneprior antidepressant medication1
- All patients who failed one prior research- grade Rx (N=164; MADRS, P=0.0006)
- Second, industry-independent RCT, sham-controlled trial funded by the NIMH
Unmatched Body of TMS Clinical Data
12 | >900 | Resulting in |
25 | ||
Studies | Patients | |
Publications | ||
Safety Record
- > 3.0 million treatment sessions delivered globally
- > 85,000 patients treated
- Adverse events discontinuation rate ~5%3
- Enrolled 199 adult patients with treatment resistant MDD
- Primary Efficacy Endpoint: Remission measured using HAMD 24 at up to 6 weeks (P=0.02)
- Basis of expanded labeling in 2014 - failed one or moreprior antidepressants2
1. | O'Reardon, J.P., et al. (2007) Biological Psychiatry, 62(11):1208-1216 | |||
10 | 2. | George, M.S., et al. (2010) Archives of General Psychiatry, now published as JAMA Psychiatry, 67(5):507-516 | ||
3. | In sham-controlled studies | |||
MDD Patient Continuum of Care
Antidepressant | ||||||||||||
Next | Switch | Next | Next | Atypical | Next | |||||||
• | Other SSRIs | Augmentation | ||||||||||
Attempt | Attempt | Attempt | Antipsychotic | Attempt | ||||||||
• | or SNRIs | Strategies | Augmentation | |||||||||
First-generation | ||||||||||||
antidepressant | ||||||||||||
medications | Electroconvulsive AttemptNext | Vagus Nerve | ||||||||||
Next | Next | Next | ||||||||||
Therapy* | Stimulation | |||||||||||
Attempt | Attempt | Attempt |
First-Line
Treatment
Attempts AttemptNext
- SSRIs
- SNRIs
TMS | TMS** | Next | |
Non-invasive | |||
Attempt | |||
Non-systemic | |||
Psychotherapy
NeuroStar Advanced Therapy is indicated for treatment of MDD in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode
- ECT may be used earlier in the patient continuum of care in patients experiencing catatonia, acute suicidal behaviors or psychotic symptoms
- TMS may be used at any point along the continuum of care following one or more failed treatment attempts
11
Our Solution: NeuroStar Advanced Therapy
NeuroStar Advanced Therapy System
Efficient
• Non-invasive and no anesthesia
• MT Assist
• Treatment time as low as 19 minutes
• TrakStar stores patient's treatment data
Therapy
- Psychiatrist establishes treatment dose and positioning in first session
- Five days a week for up to six weeks
- Trained member of office staff may administer subsequent treatment sessions under psychiatrist supervision
Precise
- Proprietary SenStar Connect contact sensing
- SenStar magnetic field detector
- Proprietary, laser-aligned,six-point coordinate system
12
Efficient, Specialty-Focused Commercialization Model
$6.0B US Addressable Market Opportunity*
# of Psychiatrists | # of Sites | # of Patients Treated | |
Total | 56,100 | 37,700 | ~7.6M Patients |
Acute Care Community + | 6,800 | 11,400 | ~2.2M Patients |
Behavioral Health | |||
Hospitals + Other Sites | |||
Solo and Group Practice | 49,300 | 26,300 | ~5.4M Patients |
Sites | |||
FAVORABLE CALL POINT DYNAMIC
Top 22% of practices | Estimated 1.6M |
represent 60% | treatable patients |
of the patient volume | $3.7B* |
or ~3.3M patients | |
Current
BDM
Call Points
Remaining 78% of practices represent 40% of the patients volume or ~2.1M patients
Estimated 1.0M treatable patients
$2.3B*
"TMS-Only"
Providers
*Represents potential revenues from treatment sessions annually, based on expected revenues for a standard course of treatment
13
Payors and Reimbursement
Payor Coverage
- Estimated to cover 95% of total private payor covered lives in the US
- 95+ major US private insurers provide coverage policies
- The top 25 US private insurers, including United/OPTUM, Anthem, Aetna, Cigna, HCSC, TRICARE and Humana, represent 205 million covered lives1 in excess of 200 million2
- 100% Medicare Coverage
- 59.7 million covered lives2
Reimbursement
- Covers MT assist and treatment sessions
CPT Code Reimbursement
90867 | MT Assist and Treatment Session |
90868 Treatment Session
90869 | Subsequent MT Assist and Treatment Session |
- As of March 15, 2018
- As of April 1, 2019
14
Physician Practice Economics
Proven return on
investment for
psychiatrists
Potential to provide | Psychiatrist can |
generate ~$7,500 to | |
meaningful | |
$10,000 of revenue | |
incremental income | |
per patient per | |
to psychiatrist | |
course of treatment | |
practice | |
on average | |
Can recoup capital
investment by
treating ~12 patients
NeuroStar Advanced Therapy has potential to enhance psychiatrist practice economics
15
Competitive Positioning
Publications from Registration Trials
Original Design Objective
3D Positioning &
Contact Sensing
Electronic Medical
Records (EMR)
Systems
Compatibility
12
Clinical
1 | 0 | 1 | 0 | 0 | 0 |
Clinical | Research/ | Research/ | Clinical | Neurosurgery | Clinical |
Neurology | Neurology | Mapping | |||
WithAdditional | Camera | |
Based | ||
Purchase |
We believe the NeuroStar Advanced Therapy System is the most attractive TMS system on the
market
16
Barriers to Entry
Barriers to
Market Entry
Proprietary technology with a broad intellectual property portfolio
Large, direct sales force
Comprehensive customer support and practice development resources
Significant body of clinical data and key opinion leader support
Significant know how and capital required to replicate our infrastructure
A market leader in TMS therapy, first mover
17
Japan Growth Opportunity
- Primary international focus is on Japan
- Third largest healthcare spend globally
- Single payor healthcare system
- Shonin Approval: September 2017
- Exclusive distribution agreement with Teijin Pharma signed October 2017
- Teijin to promote sales of systems and treatment sessions
- Minimum purchase requirements
- Milestone payments received in 2017, $2.8M
- Reimbursement listing effective June 2019
- 2nd Milestone payment received in 2019, $0.7M
- 158 hospitals qualified
- Approved reimbursement amount is ¥12,000
Estimated TAM in Japan for
Treatment Sessions1
Adults Suffering from MDD
2.4 million2
Treated by a Psychiatrist
655,0002
Failed to achieve remission
475,0003
~$600 Million Addressable Market
Japan represents a large market opportunity
1. | Assumes psychiatrist reimbursement levels per treatment course are similar to those in the U.S. | |||
18 | 2. | Source: National Center for Biotechnology and Information | ||
3. | Estimate based on Star*D data and all of whom covered by Japan's single payor healthcare system | |||
Intellectual Property
Patent Portfolio
- Largest of any TMS system provider
-
Issued or allowed patents:
37 US / 51 OUS - Pending patent applications:
7 US / 10 OUS
Key Portfolio Coverage Areas
- Contact Sensing
- Multiple, US patent expires 2024-2027
- MT Assist
- US patent expires 2024
- Iron Core Magnet
- Multiple, US patents expire 2025-2027
The largest IP portfolio of all TMS competitors, protecting our technical advantage
and ensuring freedom to operate globally
19
Management and Board of Directors
Management | ||
Steve Furlong | VP, CFO | |
Daniel Guthrie | VP, CCO | |
Greg Harper | VP, R&D, Operations and | |
Product Development | ||
Andrew Macan | SVP, General Counsel, | |
Chief Compliance Officer, and | ||
Corporate Secretary | ||
Anthony Pui | VP, International Commercial | |
Development | ||
Keith Sullivan | President and CEO | |
Yelena Tropsha | VP, Commercial Access |
Board of Directors
John Bakewell | Former EVP and CFO, Wright |
Medical Group | |
Sheryl L. Conley | Former Global President and Chief |
Marketing Officer, Zimmer Holdings | |
Brian Farley | Chairman; Former CEO and |
Chairman, Entellus Medical | |
Wilfred Jaeger | Three Arch Partners |
Glenn Muir | Former CFO, Hologic |
Bruce J. Shook | Director, President and CEO, Intact |
Vascular and Vesper Medical | |
Keith Sullivan | President and CEO, Neuronetics, |
Inc. |
20
Financial Overview
Annual Revenue
($ in millions)
Annual Revenue by Geography
$70.0
$62.7
$60.0 | $1.9 | ||||||
$52.8 | |||||||
$50.0 | |||||||
$1.3 | |||||||
$40.4 | |||||||
$40.0 | |||||||
$0.6 |
$30.0$60.8
$51.5
$20.0 $39.8
$10.0
$0.0
2017 2018 2019
US OUS
22
Annual Product Revenue (US)
$60.8
$60.0 $1.6
$51.5
$50.0 | $1.6 | +3% | ||
$39.9 | ||||
$40.0 | +19% | |||
$1.4 | $41.1 | |||
$35.3 | ||||
$30.0 | +17% | |||
$28.4 +24%
$20.0
$10.0 | +44% | +23% | ||
$14.6 | $18.0 | |||
$10.1 | ||||
$0.0 2017 2018 2019
NeuroStar Systems Treatment Sessions Other
Worldwide Quarterly Revenue ($ in millions) | $17.4 | ||||
$18 | |||||
$16.6 | $16.0 | ||||
$15.6 | |||||
$13.3 | $13.7 | ||||
$12.7 | |||||
$12.1 | $11.5 | ||||
$12 | |||||
$10.5 | |||||
$10.3 | $10.2 | ||||
$7.5 | |||||
$6 | |||||
$0 | |||||
Q1 2017Q2 2017Q3 2017Q4 2017Q1 2018Q2 2018Q3 2018Q4 2018Q1 2019Q2 2019Q3 2019Q4 2019Q1 2020 |
Q1 2020 Revenue $11.5M versus $12.7M in Q1 2019
23
Results of Operations
Year Ended | Three Months Ended | |||||
December 31, | March 31, | |||||
2018 | 2019 | 2019 | 2020 | |||
($ in thousands) | ||||||
Revenues | $52,776 | $62,656 | $12,728 | $11,476 | ||
YOY Growth | 31% | 19% | -10% | |||
Gross Profit | 40,329 | 47,267 | 9,921 | 8,665 | ||
Gross Margin | 76% | 75% | 78% | 76% | ||
Operating Expenses: | ||||||
Sales and Marketing | 38,264 | 42,993 | 9,592 | 10,723 | ||
% of Revenues | 73% | 69% | 75% | 93% | ||
General and Administrative | 13,667 | 17,457 | 4,599 | 5,287 | ||
% of Revenues | 26% | 28% | 36% | 46% | ||
Research and Development | 8,232 | 13,747 | 2,786 | 3,021 | ||
% of Revenues | 16% | 22% | 22% | 26% | ||
Total Operating Expenses | 60,163 | 74,197 | 16,977 | 19,031 | ||
Loss from Operations | ($19,834) | ($26,930) | ($7,056) ($10,366) | |||
% of Revenues | (38%) | (43%) | (55%) | (90%) | ||
24
Financial Position
($ in thousands) | As of March 31, 2020 |
Cash and Cash Equivalents | $63,647 |
Other Assets | $24,808 |
Total Assets | $88,455 |
Long-Term Debt, net | $34,210 |
Convertible Preferred Stock Warrant | $0 |
Liability | |
Convertible Preferred Stock | $0 |
Accumulated Deficit | ($262,700) |
Total Stockholders' Equity | $36,511 |
25
Supplemental Information
26
NeuroStar Unit Sales: 2018, 2019, and 2020:Q1
Unit Sales | 2018 | 2019 | 2020 | ||||||||
Q1-18 | Q2-18 | Q3-18 | Q4-18 | Q1-19 | Q2-19 | Q3-19 | Q4-19 | Q1-20 | |||
Total NeuroStar Units (Capital Sales, Sales Type Leases, Operating Leases) (1) | 30 | 47 | 48 | 65 | 43 | 61 | 68 | 78 | 38 | ||
YoY ∆ | 50% | 62% | 50% | 55% | 43% | 30% | 42% | 20% | -12% | ||
Beginning Active Installed Base | |||||||||||
752 | 781 | 816 | 858 | 907 | 931 | 976 | 1,032 | 1,085 | |||
Ending Active Installed Base | 781 | 816 | 858 | 907 | 931 | 976 | 1,032 | 1,085 | 1,119 | ||
YoY ∆ | 16% | 18% | 18% | 21% | 19% | 20% | 20% | 25% | 20% | ||
Net Active Installed Base Change | |||||||||||
29 | 35 | 42 | 49 | 24 | 45 | 56 | 53 | 34 | |||
YoY ∆ | 21% | 84% | 20% | 81% | -17% | 29% | 33% | 8% | 6% | ||
Inactive Systems (Calculation) (2) | -1 | -12 | -6 | -16 | -19 | -16 | -12 | -25 | -4 | ||
Inactive System Churn % (Calculation) (3) | -0.1% | -1.5% | -0.7% | -1.9% | -2.1% | -1.7% | -1.2% | -2.4% | -0.4% |
- = Includes all active systems placed during the period. In 2018, this included 15 operating leases: Q1-6, Q2- 4, Q3-1,Q4-4.
- = Calculation: (Ending Installed Base - Beginning Installed Base) - Total NeuroStar Units
- = Calculation: Inactive Systems / Ending of Prior Period Installed Base
27
NeuroStar Revenue: 2018, 2019, and 2020:Q1
NeuroStar Revenue | 2018 | 2019 | 2020 | ||||||||
Q1-18 | Q2-18 | Q3-18 | Q4-18 | Q1-19 | Q2-19 | Q3-19 | Q4-19 | Q1-20 | |||
Total U.S. NeuroStar Revenue ($000s) | $2,373 | $3,568 | $3,908 | $4,754 | $3,350 | $4,628 | $4,616 | $5,413 | $2,594 | ||
YoY ∆ | 80% | 42% | 38% | 37% | 41% | 30% | 18% | 14% | -23% | ||
U.S. NeuroStar Capital Revenue ($000s) (4) | |||||||||||
$1,909 | $3,268 | $3,428 | $4,338 | $2,939 | $4,034 | $4,264 | $4,959 | $2,410 | |||
YoY ∆ | 76% | 65% | 54% | 47% | 54% | 23% | 24% | 14% | -18% | ||
U.S. NeuroStar Operating Lease Revenue ($000s) (5) | |||||||||||
$258 | $181 | $269 | $231 | $182 | $187 | $184 | $177 | $155 | |||
YoY ∆ | 13% | -38% | -7% | -2% | -29% | 3% | -31% | -24% | -15% | ||
U.S. NeuroStar Other ($000s) (6) | |||||||||||
$206 | $120 | $211 | $185 | $229 | $407 | $167 | $278 | $29 | |||
YoY ∆ | NM | -50% | -34% | -35% | 11% | 239% | -21% | 50% | -87% |
- = Revenue includes NeuroStar System Capital Sales and Sales Type Leases
- = Revenue derived from Operating Lease revenue amortization during the period
- = Revenue derived from Treatment Coils in U.S.
28
NeuroStar Treatment Session: 2018, 2019, and 2020:Q1
Treatment Session Sales | 2018 | 2019 | 2020 | ||||||||
Q1-18 | Q2-18 | Q3-18 | Q4-18 | Q1-19 | Q2-19 | Q3-19 | Q4-19 | Q1-20 | |||
Total Treatment Session Revenues ($000s) | $7,240 | $8,920 | $9,218 | $9,909 | $8,778 | $10,847 | $10,252 | $11,243 | $8,193 | ||
YoY ∆ | 26% | 21% | 28% | 23% | 21% | 22% | 11% | 13% | -7% | ||
Active Installed Base (Ending of Prior Quarter) | 752 | 781 | 816 | 858 | 907 | 931 | 976 | 1,032 | 1,085 | ||
Avg. Revenue per Active System ($000s) (8) | |||||||||||
$9.6 | $11.4 | $11.3 | $11.5 | $9.7 | $11.7 | $10.5 | $10.9 | $7.6 | |||
YoY ∆ | 8% | 4% | 8% | 4% | 1% | 2% | -7% | -6% | -22% |
(8) = Total Treatment Session Revenue / Active Installed Base (Ending of Prior Quarter)
29
Neuronetics, Inc. Supplemental Financial and Operating Information
Revenue ($ thousands) | 2018 | |||
Q1 | Q2 | Q3 | Q4 | |
NeuroStar Capital (1) | $1,909 | $3,268 | $3,428 | $4,338 |
YoY Change | 76% | 65% | 54% | 47% |
NeuroStar Operating Lease (2) | $258 | $181 | $269 | $231 |
YoY Change | 13% | -38% | -7% | -2% |
Other (3) | $206 | $120 | $211 | $185 |
YoY Change | NM | -50% | -34% | -35% |
Total U.S. NeuroStar Advanced Therapy System Revenues | $2,373 | $3,568 | $3,908 | $4,754 |
YoY Change | 80% | 42% | 38% | 37% |
Total U.S. Treatment Sessions Revenues | $7,240 | $8,920 | $9,218 | $9,909 |
YoY Change | 26% | 21% | 28% | 23% |
Total U.S. Other Revenues | $359 | $410 | $392 | $426 |
YoY Change | 11% | 25% | 15% | 21% |
Total U.S. Revenues | $9,972 | $12,898 | $13,518 | $15,089 |
YoY Change | 35% | 26% | 30% | 27% |
Total International Revenues | $180 | $354 | $219 | $546 |
YoY Change | 36% | 325% | 137% | 100% |
Total Revenues | $10,152 | $13,252 | $13,737 | $15,635 |
YoY Change | 35% | 29% | 31% | 29% |
Operating and Financial Metrics | 2018 | |||
Q1 | Q2 | Q3 | Q4 | |
Active Installed Base | 816 | 858 | ||
Active Installed Base - Beginning of Period | 752 | 781 | ||
Active Installed Base - End of Period | 781 | 816 | 858 | 907 |
Total NeuroStar Systems Sold (4) | 24 | 43 | 47 | 61 |
YoY Change | 71% | 72% | 57% | 53% |
Average Revenue Per Active System ($) (5) | $9,627 | $11,421 | $11,297 | $11,549 |
YoY Change | 8% | 4% | 8% | 4% |
30
2019 | |||
Q1 | Q2 | Q3 | Q4 |
$2,939 | $4,034 | $4,264 | $4,959 |
54% | 23% | 24% | 14% |
$182 | $187 | $184 | $177 |
-29% | 3% | -31% | -24% |
$229 | $407 | $167 | $278 |
11% | 239% | -21% | 50% |
$3,350 | $4,628 | $4,616 | $5,413 |
41% | 30% | 18% | 14% |
$8,778 | $10,847 | $10,252 | $11,243 |
21% | 22% | 11% | 13% |
$418 | $415 | $426 | $374 |
16% | 1% | 9% | -12% |
$12,546 | $15,890 | $15,294 | $17,030 |
26% | 23% | 13% | 13% |
$182 | $682 | $706 | $326 |
1% | 93% | 222% | -40% |
$12,728 | $16,572 | $16,000 | $17,356 |
25% | 25% | 16% | 11% |
2019 | |||
Q1 | Q2 | Q3 | Q4 |
907 | 931 | 976 | 1,032 |
931 | 976 | 1,032 | 1,085 |
43 | 61 | 68 | 78 |
79% | 42% | 45% | 28% |
$9,678 | $11,651 | $10,504 | $10,895 |
1% | 2% | -7% | -6% |
2020 | 2018 | 2019 | ||
Q1 | FY | FY | ||
$2,410 | $12,942 | $16,196 |
-18% 57% 25%
$155 $939 $730
-15%-10%-22%
$29 $722 $1,081
-87%-15% 50%
$2,594 $14,603 $18,007
-23% 44% 23%
$8,193 $35,287 $41,120
-7% 24% 17%
$390 $1,587 $1,633
-7% 19% 3%
$11,177 $51,477 $60,760
-11% 29% 18%
$299 $1,299 $1,896
64% 124% 46%
$11,476 $52,776 $62,656
-10% | 31% | 19% |
2020 | 2018 | 2019 | ||
Q1 | FY | FY | ||
1,085 | 752 | 907 | ||
1,119 | 907 | 1,085 |
38 175 250
-12% 61% 43%
$7,551 $46,924 $45,337
-22% 7% -3%
3222 Phoenixville Pike Malvern, PA 19355 www.neurostar.com 610.640.4202
Attachments
- Original document
- Permalink
Disclaimer
Neuronetics Inc. published this content on 16 July 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 July 2020 15:25:06 UTC